# Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961

> **NCT04495140** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 6 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** [14C]PF-06882961, 50 mg
- **DRUG:** PF-06882961, 50 mg and [14C]PF-06882961, 100 ug

## Key facts

- **NCT ID:** NCT04495140
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-22
- **Primary completion:** 2020-10-15
- **Final completion:** 2020-10-15
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2020-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04495140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04495140, "Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04495140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*